The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Open-Source Automated Insulin Delivery in Type 1 Diabetes.
Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system. ⋯ In children and adults with type 1 diabetes, the use of an open-source AID system resulted in a significantly higher percentage of time in the target glucose range than the use of a sensor-augmented insulin pump at 24 weeks. (Supported by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12620000034932.).
-
Randomized Controlled Trial Multicenter Study
Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.
Whether improved glucose control with hybrid closed-loop therapy can preserve C-peptide secretion as compared with standard insulin therapy in persons with new-onset type 1 diabetes is unclear. ⋯ In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion. (Funded by the National Institute for Health and Care Research and others; CLOuD ClinicalTrials.gov number, NCT02871089.).
-
Editorial Comment
On the Path toward Expanding Treatment Options for Diabetes.